-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
NewRetinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn't a cure at this time, people can maximize their residual...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Report Overview Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, slowly progressive, often asymmetric corneal disease. FECD is a sporadic or autosomal dominant dystrophy involving the endothelial layer of the cornea. Key Mechanisms of Action (Pipeline) ·      Enzyme Inhibitor ·      Receptor Agonist ·      Protein and Peptide Inhibitor ·      Transporter Inhibitor Key Molecule Types (Pipeline) ·      Small Molecule ·      Biologic Key Routes of Administration (Pipeline) ·      Topical ·      Oral ·      Injection Top Sponsors...
-
Sector Analysis
Cell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report: Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs. Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA. Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs. Get a detailed assessment of the clinical trials taking place within the...